Petya Kamenova
Clinical Center of Endocrinology and Gerontology, Medical University,
No 2, Zdrave str., 1431, Sofia
Bulgaria
Research Article
Metformin Reduces Cardiometabolic Risk Factors in People at High Risk for Development of Type 2 Diabetes and Cardiovascular Disease
Author(s): Petya Kamenova, Iliyana Atanasova and Georgi KirilovPetya Kamenova, Iliyana Atanasova and Georgi Kirilov
Background: The aim of the study was to investigate the effect of metformin on cardiometabolic risk factors as visceral obesity, hyperinsulinaemia, insulin resistance, dyslipidaemia and arterial hypertension in hyperinsulinaemic normal glucose tolerant people with metabolic syndrome who represent a high-risk group for development of type 2 diabetes and cardiovascular disease.
Methods: 52 participants (20 men/32 women) of mean age 40.1 ± 14.2 yrs were included in an open-label prospective one year observational clinical study in which cardiometabolic risk markers at three months intervals were followed. Metformin was applied at a mean dose of 2.55 ± 0.2 g daily on a usual diet and physical activity.
Results: Body mass index, waist circumference, fasting serum insulin and homeostasis model assessment of insul.. View More»
